2026-W46 · Nov 9–Nov 15 · Company · Profile · published
DexCom company profile · continuous glucose monitoring (CGM) systems · history · financial snapshot · S&P 500 rank #314 · 德康公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | DXCM (Nasdaq) |
| Company | DexCom, Inc. |
| GICS sector / industry | Health Care / Health Care Equipment |
| S&P 500 rank (by weight) | #314 · 0.05% (Nov 3, 2026) |
| Sector rank (by S&P 500 weight) | #42 in Health Care (Nov 3, 2026) |
| Headquarters | San Diego, California |
| Founded | 1999 |
| CEO | Jacob S. Leach |
| Employees | ≈11,100 (Dec 31, 2025, FY2025 10-K) |
| Market cap | $31.61B (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 0001093557 |
WHAT IT DOES
DexCom designs, manufactures and sells continuous glucose monitoring (CGM) systems for diabetes and metabolic-health management. Its G7 system, cleared in the United States for people with diabetes aged two and older, and the G7 15 Day system, cleared in April 2025 for adults, give real-time glucose readings without routine fingersticks and connect to phones, watches and insulin-delivery partners.
FY2025 revenue was $4,662.0M, up 16% from $4,033.0M in FY2024, and net income was $836.3M, up 45% from $576.2M. Gross profit was $2,801.9M, a 60.1% gross margin (computed: gross profit divided by revenue). The United States supplied 71.5% of revenue and international markets 28.5%. DexCom sells through distributors (84.9% of revenue, computed) and directly (15.1%, computed).
Beyond diabetes, DexCom launched Stelo in August 2024 as the first over-the-counter glucose biosensor in the United States, aimed at adults with prediabetes and Type 2 diabetes who do not use insulin. Manufacturing sits in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland, with headquarters and research in San Diego.
REVENUE BY GEOGRAPHY — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| United States | $3,334.9M | 71.5% | +15% |
| International | $1,327.1M | 28.5% | +16% |
| Total revenue | $4,662.0M | 100% | +16% |
HISTORY
| Year | Milestone |
|---|---|
| 1999 | Founded in San Diego, California, to develop continuous glucose monitoring technology |
| 2006 | Receives FDA approval and commercializes its first CGM product |
| 2018 | G6 receives FDA marketing authorization, the first CGM permitted as part of an integrated system with compatible devices |
| 2023 | G7 launches, with FDA authorization in December 2022 and CE Mark in March 2022 |
| 2024 | Stelo launches in August as the first over-the-counter glucose biosensor in the United States |
| 2025 | G7 15 Day receives FDA marketing authorization in April; DexCom says it will transition G6 customers to G7 and G7 15 Day by the end of 2026 |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Revenue | $4,662.0M (+16% YoY) |
| Cost of sales | $1,860.1M |
| Gross profit | $2,801.9M (60.1% margin, computed) |
| Research and development | $599.1M |
| Selling, general and administrative | $1,291.0M |
| Operating income | $911.8M (vs $600.0M in FY2024) |
| Net income | $836.3M (+45% YoY) |
| Diluted EPS | $2.09 (vs $1.42 in FY2024) |
| Total assets | $6,339.9M (Dec 31, 2025) |
| Stockholders’ equity | $2,746.0M (Dec 31, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
DexCom is the S&P 500’s pure-play CGM name at a 0.05% weight and Health Care rank #42: it gives the index its cleanest exposure to diabetes-technology adoption, sensor volumes and the shift from fingerstick testing to continuous data.
Its results are also a read on consumer-health reimbursement: payer coverage decisions and distributor sell-through move DexCom revenue before they move broader medical-device demand.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source) |
| Financials | DexCom FY2025 Form 10-K (fiscal year ended Dec 31, 2025; filed Feb 12, 2026, SEC EDGAR) |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | DXCM(Nasdaq) |
| 公司 | DexCom, Inc. |
| GICS 板塊/行業 | 醫療保健/Health Care Equipment |
| 標普500排名(按權重) | 第314名 · 0.05%(2026 年 11 月 3 日) |
| 板塊內排名(按標普500權重) | 醫療保健第42名(2026 年 11 月 3 日) |
| 總部 | 美國加州聖地牙哥 |
| 成立 | 1999年 |
| 行政總裁 | Jacob S. Leach |
| 員工 | 約11,100人(2025年12月31日,FY2025 10-K) |
| 市值 | $31.61B(2026 年 11 月 3 日) |
| SEC 文件 | EDGAR — CIK 0001093557 |
業務概覽
德康設計、製造及銷售連續血糖監測(CGM)系統,用於糖尿病及代謝健康管理。G7系統已在美國獲批供兩歲及以上糖尿病患者使用,G7 15 Day系統於2025年4月獲批供成人使用,可提供即時血糖讀數,無需常規指尖採血,並可連接手機、手錶及胰島素輸送合作夥伴產品。
FY2025收入為46.620億美元,較FY2024的40.330億美元增長16%;淨利潤為8.363億美元,較5.762億美元增長45%。毛利為28.019億美元,毛利率60.1%(計算值:毛利除以收入)。美國佔收入71.5%,國際市場佔28.5%。德康透過經銷商銷售(佔收入84.9%,計算值)及直接銷售(15.1%,計算值)。
除糖尿病外,德康於2024年8月推出Stelo,作為美國首款非處方血糖生物感測器,面向未使用胰島素的前期糖尿病及2型糖尿病成人。生產基地位於亞利桑那州梅薩、馬來西亞峇都加灣及愛爾蘭雅典萊,總部及研發中心位於聖地牙哥。
按地區劃分的收入 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 美國 | $3,334.9M | 71.5% | +15% |
| 國際 | $1,327.1M | 28.5% | +16% |
| 收入總計 | $4,662.0M | 100% | +16% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1999年 | 於加州聖地牙哥成立,開發連續血糖監測技術 |
| 2006年 | 獲FDA批准並商業化首款CGM產品 |
| 2018年 | G6獲FDA上市許可,成為首款可作為綜合系統一部分與兼容設備配合使用的CGM |
| 2023年 | G7推出;2022年12月獲FDA許可,2022年3月獲CE標誌 |
| 2024年 | Stelo於8月推出,成為美國首款非處方血糖生物感測器 |
| 2025年 | G7 15 Day於4月獲FDA上市許可;德康表示將於2026年底前把G6客戶轉移至G7及G7 15 Day |
競爭地位
財務快照 — FY2025
| 收入 | $4,662.0M(同比+16%) |
| 銷售成本 | $1,860.1M |
| 毛利 | $2,801.9M(毛利率60.1%,計算值) |
| 研發 | $599.1M |
| 銷售、一般及行政 | $1,291.0M |
| 營業利潤 | $911.8M(FY2024為$600.0M) |
| 淨利潤 | $836.3M(同比+45%) |
| 攤薄每股收益 | $2.09(FY2024為$1.42) |
| 總資產 | $6,339.9M(2025年12月31日) |
| 股東權益 | $2,746.0M(2025年12月31日) |
主要風險
對標普500的重要性
德康是標普500中純CGM公司,權重0.05%,醫療保健板塊第42名:它為指數提供最直接的糖尿病技術採用、感測器銷量及從指尖採血轉向連續數據的敞口。
其業績亦是消費健康報銷的晴雨表:付款方覆蓋決定及經銷商銷售會先於整體醫療器械需求反映在德康收入上。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源) |
| 財務 | DexCom FY2025 10-K(財政年度截至2025年12月31日;2026年2月12日提交,SEC EDGAR) |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 08:26 · updated 2026-11-14 23:21 · rev 6